Profile | GDS2987 / GI_40786533-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 2.2 | 8 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 47.9 | 64 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 3.9 | 7 |
GSM215294 | HMVEC_SLx2119_rep1 | 6.3 | 23 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 17.4 | 27 |
GSM215298 | PASMC_vehicle_rep2 | 13 | 20 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 4.2 | 8 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | 53.3 | 60 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 38.5 | 58 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 3.5 | 6 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 34.7 | 53 |
GSM215329 | PASMC_SLx2119_rep3 | 19.8 | 36 |
GSM215330 | Fibroblasts_vehicle_rep1 | 13 | 30 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | 30.4 | 59 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 6.7 | 19 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 14.1 | 34 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 3.5 | 12 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 5.9 | 17 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 20.9 | 51 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 18.1 | 42 |